FNCH - Update On Evogene's Subsidiaries: Biomica Lavie Bio And AgPlenus

• Evogene acts as a computational biology technology hub; $50M market cap, $54M cash, 5 subsidiaries (4 of which are valuable). The article discusses subsidiaries Biomica, Lavie Bio and AgPlenus.
• Biomica's lead product BMC128, 4 strain live microbiome consortia in immuno-oncology, is proceeding to clinical trials in Israel in Q2 2022, in combination with Bristol Myers' PD-1 Opdivo.
• Lavie Bio recently commercially launched result™, a microbiome-based ag-stimulant to increase yield and profitability in spring wheat. Modest initial 2022 sales are expected to increase in 2023 and beyond.
• AgPlenus is an ag-chemical company. Its lead product APH1 is a novel mode of action herbicide in the near "optimized lead" stage. A deal for APH1could be announced this year.
• The author believes that Evogene is currently undervalued. With numerous upcoming catalysts in 2022/2023, patient risk-tolerant investors could be handsomely rewarded in the next few years.

For further details see: